SPECIFICITY OF POLYCLONAL ANTIBODIES RAISED AGAINST A NOVEL 24,25-DIHYDROXYVITAMIN-D-3-BOVINE SERUM-ALBUMIN CONJUGANT LINKED THROUGH THE C-11-ALPHA OR C-3 POSITION
N. Kobayashi et al., SPECIFICITY OF POLYCLONAL ANTIBODIES RAISED AGAINST A NOVEL 24,25-DIHYDROXYVITAMIN-D-3-BOVINE SERUM-ALBUMIN CONJUGANT LINKED THROUGH THE C-11-ALPHA OR C-3 POSITION, Journal of steroid biochemistry and molecular biology, 62(1), 1997, pp. 79-87
Novel hapten-carrier conjugants were prepared by coupling 11 alpha-hem
iglutaryloxy-(24R)-24,25-dihydroxyvitamin D-3 or (24R)-23,25-dihydroxy
vitamin D-3 [24,25(OH)(2)D-3] 3-hemiglutarate with bovine serum albumi
n (BSA), to obtain an antibody with high specificity and affinity for
use in 24,25(OH)(2)D-3 immunoassay. The polyclonal antibodies showing
high titre were each elicited in three or four rabbits against these t
wo conjugants; the antibodies obtained from the former and the latter
conjugants were expressed as Ab11 and Ab3, respectively. These had a m
uch higher affinity for 24,25(OH)(2)D-3 than that of the vitamin D bin
ding protein (DBP). Specificity of the antibodies was investigated by
crossreactivities with 11 related compounds in a radioimmunoassay (RIA
) system. The Ab11 well discriminated the 1 cc-hydroxylated metabolite
s such as 1,24,25(OH)(3)D-3 (less than or equal to 0.69%) and 1,25(OH)
(2)D-3 (less than or equal to 0.25%), but significantly crossreacted w
ith some side chain modified compounds such as (24S)-24,25-dihydroxyvi
tamin D-3 [24S,25(OH)(2)D-3] (greater than or equal to 67%), 25(OH)D-3
(greater than or equal to 14%) and 25,26(OH)(2)D-3 (greater than or e
qual to 23%). On the other hand, the Ab3 showed only negligible crossr
eactivities with the compounds having a different side chain structure
such as 24S,25(OH)(2)D-3 (less than or equal to 3.0%), 25(OH)D-3 (<0.
3%) and 25,26(OH)(2)D-3 (less than or equal to 0.53%). A significant c
rossreaction was found only with 1,24,25(OH)(3)D-3 (greater than or eq
ual to 68%). These results demonstrated that the Ab3 are promising for
developing an immunoassay system which is much more specific and sens
itive than conventional competitive protein binding assays based on DB
P. (C) 1997 Elsevier Science Ltd.